Note 13 - Share-Based Compensation

12 Months Ended

Dec. 31, 2013

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

NOTE 13 – Share-Based Compensation:

In 2003, the stockholders of the Company approved the 2003 Incentive Stock and Awards Plan (the “2003 Plan”), authorizing the granting of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock, performance stock and other stock based compensation. This plan expired in May of 2013, at which time, the stockholders of the Company approved the 2013 Incentive Stock and Awards Plan (the “2013 Plan”), authorizing the granting of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock, performance stock and other stock based compensation. A total of 2,500,000 shares of common stock (subject to adjustment for expirations and cancellations of options outstanding from the 2003 Plan subsequent to its termination) have been reserved for issuance under the 2013 Plan. All awards under both plans have been or will be granted at prices at least equal to the fair market value of the shares on the date of grant. Awards (all of which are exercisable at each respective year end) granted to date under both plans are exercisable in part or in full within five years of grant date with the exception of annual grants to outside directors which are exercisable in part or in full within ten years of grant date. Proceeds from the exercise of awards are credited to common stock to the extent of par value, and the balance is credited to additional paid-in capital. At December 31, 2013, the Company had 2,484,281 shares of common stock authorized for awards of share-based compensation under the 2013 Plan. A summary of option transactions during the two years ended December 31, 2013 follows:

	No. of Shares			Weighted Average Exercise Price
Outstanding December 31, 2011		671,500		$	10.66
Granted		194,223			12.62
Exercised		(138,252	)		9.32
Lapsed		(86,400	)		12.57
Cancelled		(26,154	)		12.37
Outstanding December 31, 2012		614,917		$	11.24
Granted		202,884			11.43
Exercised		(206,441	)		10.73
Lapsed		(31,150	)		10.68
Cancelled		(23,181	)		11.67
Outstanding December 31, 2013		557,029		$	11.51

At December 31, 2013, options outstanding, all of which were fully vested and exercisable, had an intrinsic value of $2,214,000.

Options exercised during the years ended December 31, 2013 and 2012, had intrinsic values of $796,000 and $269,000, respectively.

The weighted average fair value of options granted for each of the years ended December 31, 2013 and 2012, was $3.01 and $3.38, respectively.

The following table summarizes information about stock options outstanding as of December 31, 2013:

Range of Exercise Price			Shares		Weighted Average Remaining Contractual Life (Years)		Weighted Average Exercise Price
$7.63	-	$9.80		97,094		2.28	$	9.45
$11.10	-	$13.15		449,935		3.57	$	11.86
	$16.00			10,000		0.33	$	16.00
$7.63	-	$16.00		557,029		3.29	$	11.51

A summary of stock-settled stock appreciation rights (SARS") transactions during the two years ended December 31, 2013 follows:

	No. of Shares			Weighted Average Exercise Price
Outstanding December 31, 2011		257,424		$	11.32
Granted		65,752			13.15
Exercised		(134,304	)		11.67
Lapsed		-			-
Cancelled		(12,396	)		13.15
Outstanding December 31, 2012		176,476		$	11.60
Granted		59,716			11.29
Exercised		(9,786	)		11.73
Lapsed		-			-
Cancelled		-			-
Outstanding December 31, 2013		226,406		$	11.52

At December 31, 2013, SARS outstanding, all of which were fully vested and exercisable, had an aggregate intrinsic value of $898,000.

There were 9,786 SARS exercised during the year ended December 31, 2013. SARS exercised during the year ended December 31, 2013 had an intrinsic value of $36,000. There were 134,304 SARS exercised during the year ended December 31, 2012. SARS exercised during the year ended December 31, 2012 had an intrinsic value of $122,000.

The weighted average fair value of SARS granted for each of the years ended December 31, 2013 and 2012 was $2.97 and $3.59, respectively.

The following table summarizes information about SARS as of December 31, 2013:

Range of Exercise Price			SARS		Weighted Average Remaining Contractual Life (Years)		Weighted Average Exercise Price
	$9.80			26,184		1.08	$	9.80
$11.24	-	$13.15		200,222		2.89	$	11.74
$9.80	-	$13.15		226,406		2.68	$	11.52

At December 31, options and SARS available to issue were 2,484,281 for 2013 and 1,284,675 for 2012. Options and SARS have never been repriced by the Company in any year.

The following table summarizes significant assumptions utilized to determine the fair value of share-based compensation awards:  

	SARS			Options
Exercise price
2013	$	11.29			$11.29	-	$11.76
2012	$	13.15			$11.72	-	$13.15
Market price
2013	$	11.29			$11.29	-	$11.76
2012	$	13.15			$11.72	-	$13.15
Risk free interest rate (1)
2013		0.9	%		0.9%	-	1.7%
2012		0.8	%		0.7%	-	1.9%
Expected award life (years) (2)		5			5	-	10
Expected volatility (3)
2013		46.0	%		36.7%	-	46.0%
2012		45.1	%		36.4%	-	45.9%
Expected dividend yield (4)
2013		4.8	%		4.6%	-	4.8%
2012		4.1	%		4.1%	-	4.6%

(1) The risk-free interest rate is based on the yield of a U.S. treasury bond with a similar maturity as the expected life of the awards.

(2) The expected life in years for awards granted was based on the historical exercise patterns experienced by the Company when the award is made.

(3) The determination of expected stock price volatility for awards granted in each of the two years ended December 31, was based on historical Superior common stock prices over a period commensurate with the expected life.

(4) The dividend yield assumption is based on the history and expectation of the Company’s dividend payouts.

For the years ended December 31, 2013 and 2012, the Company recognized $788,000 and $893,000, respectively, of pre-tax share-based compensation expense, recorded in selling and administrative expense in the consolidated statements of comprehensive income. These expenses were offset by $72,000 and $96,000, respectively, of deferred tax benefits for non-qualified share–based compensation. As of December 31, 2013, the Company had no unrecognized compensation cost for share-based awards based upon the Company’s standard vesting policies, which provide for immediate vesting at the date of grant.

During the years ended December 31, 2013 and 2012, the Company received $2,216,000 and $889,000, respectively, in cash from stock option exercises. Current tax benefits of $270,000 and $60,000, respectively, were recognized for these exercises. Additionally, during the year ended December 31, 2012, the Company received 34,073 shares of its common stock as payment for the issuance of 41,596 shares of its common stock related to the exercise of stock option agreements.